Browse > Article
http://dx.doi.org/10.7742/jksr.2013.7.3.251

The Study and Measurement of Three Dimensional Spatial Dose Rate from Radioiodine Therapy  

Chang, Boseok (Department of Image Information Engineering, Pusan National University)
Publication Information
Journal of the Korean Society of Radiology / v.7, no.3, 2013 , pp. 251-257 More about this Journal
Abstract
Spatial dose rates of high dose $^{131}I$ therapy patients were Measured Three dimensional (X, Y, Z) distributions. I have constructed geometrical an aluminum support structure for spatial dose meters placed in 5 different heights, 8 different azimuthal angles, 6 different time interval and distance 100 cm from High dose$^{131}I$ therapy patients. when the height of vertical plane Spatial dose distribution is 100 cm, the Spatial dose rates is max and the error range is low. the vertical plane Spatial dose rates was found to be 71.85 ${\mu}Sv/h$ on the average at a distance of 100 cm, height 100 cm, from the patients 24 hours after $^{131}I$ oral administration. I divided 12 patients into two groups. I have analysed group A (drinking 5 L water) and group B (drinking 3 L water) in order to measure decrease spatial dose rates. I have found the spatial distributions of patient dose rates is $44.9{\pm}7.2$ ${\mu}Sv/h$ in group A and $100.3{\pm}8.1$ ${\mu}Sv/h$ in group B by 24 after $^{131}I$ oral administration. the reduction factor was found to be approximately 54 % through drinking 5 L water during 24 hours.
Keywords
I-131; Radioiodine; spatial dose rate; thyroid therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Health insurance Review & Assesment service of Korea. statistical data. 2010
2 Harbert JC. Radioiodine therapy of differentiated thyroid carcinoma. Nuclear Medical therapy. New York Thiem Medical Publishers p.36-90, 1987
3 ICRP: Recommendations of the international commission on Radiological Protection,ICRP Publication 26, Pergamon Press, Oxford, New York, 1977
4 Goldsmith SJ, Malblant JC, Nuclear Oncology. Philadelphia Lippincott Williams & Wilkin, pp.195-220. 2001
5 Lubin, E. Definitive improment in the approach to the treated patient as a radioactive source. J Nucl Med, Vol 43, No. 3, pp 364-5, Mar 2002
6 Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line source versus point source model. J Nucl Med Vol. 43, No. 9, pp 124-4, 2002
7 Gui-Won Lee. Minimized Radiation dose of patients receiving high dose radioiodine therapy. JKRS, Vol. 30. No. 4, pp 435-442, 2007
8 C.G Kim, Are Medical personnel safe from radiation exposure from patient receiving radioiodine ablation therapy. Nucl Med Mol Imaging Vol. 43. No. 4, Aug 2009
9 B.S Chang, S.H Kim, J.K Ahn., Radiation dose rate PET-scan patients injection with F-18-FDG, NPSM, Vol. 62, No. 12, pp. 1345-1350, December 2010.
10 M. Elschot et al, The influence of self-absorption on pet/ct shielding requirements, J Med. Phys Vol. 37, No 6, pp. 2999-3007, June 2010.   DOI   ScienceOn
11 Korea Atomic Energy Research Institute, Certificate for Detector Calibration, 2013
12 ICRP Publication 94, Release of patients after therapy with unsealed radionuclides, pp 53-58, Ann. ICRP 34 (2), 200